A TLR7 agonist strengthens T and NK cell function during BRAF‐targeted therapy in a preclinical melanoma model

Por Bellmann, Lydia, Cappellano, Giuseppe, Schachtl‐Riess, Johanna F., Prokopi, Anastasia, Seretis, Athanasios, Ortner, Daniela, Tripp, Christoph H., Brinckerhoff, Constance E., Mullins, David W., Stoitzner, Patrizia
Publicado no Int J Cancer (2019)